Casdatifan showed promising clinical activity in clear cell RCC, with response rates between 25% and 33% across dosage cohorts. The 100 mg/day dosage of casdatifan is planned for future combination ...

“Interestingly, the confirmed response rate in the intention to treat population was 32%, but this increases to 53% in the MET driven subset,” says Francesca Jackson-Spence, MBChB, BMedSc, MRCP. In ...

Disitamab vedotin plus toripalimab demonstrated a 63.6% pathologic complete response rate in HER2-expressing MIBC patients. The 12-month event-free survival rate was 92.5%, indicating promising ...

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

"The median progression-free survival and median overall survival continue to be almost double what we see with chemotherapy," says Gopa Iyer, MD. In this video, Gopa Iyer, MD, shares findings from an ...

"I think this is the next step for testing the clinical activity of this agent," says David A. Braun, MD, PhD. In this video, David A. Braun, MD, PhD, describes background and design of the phase 2 ...

ORR was 70% (95% CI, 55-82) in cohort 1 compared with 31% (95% CI, 19-45) in cohort 2. Durable antitumor activity continued to be seen with combination treatment with belzutifan (Welireg) plus ...

Avelumab plus BSC significantly prolongs OS and PFS in advanced urothelial carcinoma, regardless of diabetes mellitus status. The study included 700 patients, with a balanced distribution of diabetes ...

“These data reinforce enfortumab vedotin and pembrolizumab as the new standard of care in frontline urothelial cancer," says Thomas Powles, MD, PhD. Additional follow-up data from the phase 3 EV-302 ...

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23.5 months.